secwatch / observer
8-K filed July 7, 2022, 7:59 PM ET ticker SYRE CIK 0001636282
leadership confidence high sentiment neutral materiality 0.25

Aeglea BioTherapeutics director Sandesh Mahatme resigns, effective July 8, 2022

Spyre Therapeutics, Inc.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Sandesh Mahatme

Class I Director
SYRE · Spyre Therapeutics, Inc.
Effective
2022-07-08
Filed
July 7, 2022, 7:59 PM ET
On July 6, 2022, Sandesh Mahatme advised the Board of Directors (the “Board”) of Aeglea BioTherapeutics, Inc. (the “Company”) that he would resign as a Class I director of the Board, effective on July 8, 2022.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Sandesh Mahatme resigned as Class I Director at Spyre Therapeutics, Inc..

Action
resigned
Role
Class I Director
Exact text from the filing
On July 6, 2022, Sandesh Mahatme advised the Board of Directors (the “Board”) of Aeglea BioTherapeutics, Inc. (the “Company”) that he would resign as a Class I director of the Board, effective on July 8, 2022.
View on SEC.gov

Spyre Therapeutics, Inc. filing history →

Source: SEC EDGAR
accession 0001193125-22-189446
view filing index on sec.gov
view primary document
Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.